<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Oculopharyngeal, distal, and congenital muscular dystrophies</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Oculopharyngeal, distal, and congenital muscular dystrophies</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Oculopharyngeal, distal, and congenital muscular dystrophies</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Basil T Darras, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas R Nordli, Jr, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeremy M Shefner, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Dashe, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 21, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The muscular dystrophies are an inherited group of progressive myopathic disorders resulting from defects in a number of genes required for normal muscle function. Some of the genes responsible for these conditions have been identified. Muscle weakness is the primary symptom.</p><p>The pathogenesis, genetics, and clinical characteristics of oculopharyngeal, distal, and congenital muscular dystrophies are discussed here. Other muscular dystrophies are presented separately. (See  <a class="medical medical_review" href="/d/html/6149.html" rel="external">"Duchenne and Becker muscular dystrophy: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/6185.html" rel="external">"Emery-Dreifuss muscular dystrophy"</a> and  <a class="medical medical_review" href="/d/html/87096.html" rel="external">"Facioscapulohumeral muscular dystrophy"</a> and  <a class="medical medical_review" href="/d/html/6190.html" rel="external">"Limb-girdle muscular dystrophy"</a> and  <a class="medical medical_review" href="/d/html/5147.html" rel="external">"Myotonic dystrophy: Etiology, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H9"><span class="h1">OCULOPHARYNGEAL MUSCULAR DYSTROPHY</span><span class="headingEndMark"> — </span>Oculopharyngeal muscular dystrophy (OPMD) is a rare myopathy that is characterized by ocular and pharyngeal muscle involvement, leading to ptosis and dysphagia [<a href="#rid1">1,2</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>OPMD typically presents with ptosis, dysarthria, and dysphagia. It can also be associated with proximal and distal extremity weakness. The onset is usually in middle age with asymmetric involvement of the levator palpebrae muscles. Progressive extraocular weakness subsequently develops. In general, OPMD is a slowly progressive myopathy. However, ptosis can occlude vision, and severe dysphagia may lead to weight loss and death if not treated.</p><p class="headingAnchor" id="H11"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>OPMD is distinguished from facioscapulohumeral dystrophy (FSHD) by the different distributions of weakness. Extraocular weakness is far more severe in OPMD. (See  <a class="medical medical_review" href="/d/html/87096.html" rel="external">"Facioscapulohumeral muscular dystrophy"</a>.)</p><p>OPMD is distinguished from myotonic dystrophy because myotonia is absent in the former. Ocular muscle involvement is rarely severe in early myotonic dystrophy. (See  <a class="medical medical_review" href="/d/html/5147.html" rel="external">"Myotonic dystrophy: Etiology, clinical features, and diagnosis"</a>.)</p><p>Differentiation from a mitochondrial myopathy may be more difficult. However, mitochondrial myopathies often have associated features such as retinitis pigmentosa, ataxia, elevated cerebrospinal fluid protein, cardiac conduction defects, and developmental delay that are absent in OPMD. (See  <a class="medical medical_review" href="/d/html/6193.html" rel="external">"Approach to the metabolic myopathies"</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Laboratory studies</span><span class="headingEndMark"> — </span>Muscle biopsy shows variation of fiber size and "rimmed" vacuoles. Serum creatine kinase (CK) levels may be elevated. In a study of 168 patients with genetically confirmed OPMD, muscle magnetic resonance imaging (MRI) showed fatty replacement in 97 percent of symptomatic patients [<a href="#rid3">3</a>]; early fat replacement involving the tongue, adductor magnus, and the soleus muscles may be useful in differentiating OPMD from mitochondrial and other myopathies.</p><p class="headingAnchor" id="H13"><span class="h2">Genetics</span><span class="headingEndMark"> — </span>OPMD is a genetic myopathy with mainly autosomal dominant inheritance. The prevalence of autosomal dominant OPMD is relatively high in the Canadian province of Quebec, where it is estimated at 1:1000 individuals [<a href="#rid2">2</a>]. The prevalence of autosomal dominant OPMD in France is lower at 1:100,000 individuals. The estimated prevalence of autosomal recessive OPMD in Quebec and France is 1:10,000 [<a href="#rid2">2</a>]. A single founder chromosome appears to be responsible for OPMD in the French-Canadian population [<a href="#rid4">4</a>]. The disease has also been described in the Uzbek Jews living in Israel [<a href="#rid5">5,6</a>], and in Ashkenazi Jews [<a href="#rid1">1</a>] and Hispanic populations in the United States [<a href="#rid7">7,8</a>].</p><p>Most cases of OPMD are caused by a GCN trinucleotide repeat expansion (where "N" represents any A, C, G, or T nucleotide) in the first exon of the <em>PABPN1 </em>gene [<a href="#rid9">9</a>]. The normal <em>PABPN1</em> gene contains 10 repeats [<a href="#rid2">2</a>]. In OPMD, autosomal dominant inheritance occurs with expanded alleles that range from 12 to 17 repeats. Autosomal recessive inheritance has been reported with alleles that have 11 repeats [<a href="#rid10">10-12</a>], as has at least one case of probable autosomal dominant inheritance [<a href="#rid13">13</a>]. The GCN repeat is relatively short, with small and relatively stable expansions. The polyadenylate binding protein nuclear 1 localizes to the nucleus, where it seems to be involved in messenger RNA (mRNA) polyadenylation [<a href="#rid14">14</a>]. Although data are not entirely consistent, one study from France of 354 unrelated index cases suggests that longer expansions are correlated with earlier diagnosis and greater disease severity [<a href="#rid15">15</a>]. In a Japanese patient, OPMD was caused by a <em>PABPN1</em> c.35G&gt;C pathogenic variant, which mimicked the effect of the GCN repeat expansion [<a href="#rid16">16</a>].</p><p>A severe form of OPMD with earlier onset and faster progression has been reported in patients who are homozygotes for the PABPN1 gene [<a href="#rid17">17,18</a>].</p><p>Ten families with severe, progressive muscular dystrophy, phenotypically very similar to OPMD but with much earlier onset, have been described; the condition was caused by heterozygous frameshift variants in the <em>HNRNPA2B1</em> gene [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H14"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>Treatment is supportive. In a small number of patients, cricopharyngeal myotomy has been attempted with improvement of the dysphagia [<a href="#rid20">20</a>]. In a retrospective report of 24 patients with OPMD, botulinum toxin injections into the cricopharyngeal muscle improved swallowing in 59 percent; however, various adverse events like dysphonia (24 percent) and deterioration of swallowing function (14 percent) occurred in 44 percent of these patients [<a href="#rid21">21</a>]. Severe ptosis that occludes vision can be corrected surgically, but, unfortunately, postoperative complications are common and include sling infection or exposure, keratopathy, overcorrection or undercorrection, and lagophthalmos [<a href="#rid22">22</a>]. Approaches to prevent aspiration and ensure good nutrition can be life-saving in the population of patients with severe dysphagia [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H15"><span class="h1">DISTAL MUSCULAR DYSTROPHIES</span><span class="headingEndMark"> — </span>Distal muscular dystrophies are a heterogeneous group of myopathies (<a class="graphic graphic_table graphicRef51980" href="/d/graphic/51980.html" rel="external">table 1</a>) that include the following types [<a href="#rid24">24-31</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Nonaka myopathy</p><p class="bulletIndent1"><span class="glyph">●</span>Miyoshi muscular dystrophy 1</p><p class="bulletIndent1"><span class="glyph">●</span>Miyoshi muscular dystrophy 3</p><p class="bulletIndent1"><span class="glyph">●</span>Welander distal myopathy</p><p class="bulletIndent1"><span class="glyph">●</span>Udd distal myopathy (tardive tibial muscular dystrophy)</p><p class="bulletIndent1"><span class="glyph">●</span>Markesbery-Griggs late onset distal myopathy (zaspopathy)</p><p class="bulletIndent1"><span class="glyph">●</span>Distal myotilinopathy</p><p class="bulletIndent1"><span class="glyph">●</span>Laing distal myopathy (MPD1coll)</p><p class="bulletIndent1"><span class="glyph">●</span>Distal myopathy with vocal cord and pharyngeal dysfunction (MPD2)</p><p class="bulletIndent1"><span class="glyph">●</span>Distal myopathy 3, Finnish (MPD3)</p><p class="bulletIndent1"><span class="glyph">●</span>Williams distal myopathy (MPD4)</p><p class="bulletIndent1"><span class="glyph">●</span>Distal myopathy with pes cavus and areflexia (vacuolar neuromyopathy)</p><p class="bulletIndent1"><span class="glyph">●</span>Distal myopathy with rimmed vacuoles due to <em>SQSTM1</em> pathogenic variants</p><p></p><p>These disorders are characterized by weakness that starts distally in the arms and/or legs and gradually progresses to affect proximal muscles. Almost all forms of distal myopathy can present as early as the second decade, although the onset is usually between 40 and 60 years of age.</p><p class="headingAnchor" id="H16"><span class="h1">CONGENITAL MUSCULAR DYSTROPHIES</span><span class="headingEndMark"> — </span>The term congenital muscular dystrophy (CMD) was initially applied to infants who were hypotonic and weak at birth and had findings consistent with muscular dystrophy on muscle biopsy. The recognition of multiple genetic forms of CMD and milder variants has broadened the definition to include muscular dystrophies with onset in the first two years after birth (<a class="graphic graphic_table graphicRef67132" href="/d/graphic/67132.html" rel="external">table 2</a>) [<a href="#rid32">32-35</a>]. Arthrogryposis (contracture of two or more joints at birth) is commonly observed in the newborn period. The serum creatine kinase (CK) concentration is usually elevated, and muscle biopsy is characteristically abnormal with extensive fibrosis, degeneration, and regeneration of muscle fibers and proliferation of fatty and connective tissue. In some cases, the clinical course is static but, in most patients, it progresses very slowly. However, actual improvement has been observed in a few cases.</p><p>The original classification of the CMDs was based mainly upon the presence or absence of structural central nervous system abnormalities detected by neuroimaging or at autopsy (<a class="graphic graphic_table graphicRef54811" href="/d/graphic/54811.html" rel="external">table 3</a>). The absence of structural changes distinguished "occidental" or "classic" CMD from "syndromic" forms of CMD such as Fukuyama muscular dystrophy, Walker-Warburg syndrome, or muscle-eye-brain disease. However, the distinction is not entirely precise, as structural lesions have been described in some cases of classic CMD [<a href="#rid36">36</a>]. Cognitive impairment is a frequent manifestation of CMD, particularly in patients with structural brain lesions, although it has also been detected in patients with CMD and normal brain magnetic resonance imaging (MRI) [<a href="#rid37">37</a>].</p><p>The syndromic CMDs are caused by defective post-translational modification of alpha-dystroglycan (dystroglycanopathies) and other proteins, and are caused by pathogenic variants in multiple genes (<a class="graphic graphic_table graphicRef67132" href="/d/graphic/67132.html" rel="external">table 2</a>). Dystroglycanopathies are characterized clinically by the involvement of multiple organ systems, severe brain malformations, and developmental delay [<a href="#rid38">38</a>].</p><p>Cardiac involvement ranges from absent or mild to severe, and is most often associated with dystroglycanopathies such as Fukuyama type, Walker-Warburg syndrome, and muscle-eye-brain disease [<a href="#rid39">39</a>]. Cardiac involvement is also seen in merosin-deficient CMD. In a database search of articles from PubMed, Embase, and Cochrane, cardiac abnormalities, primarily left ventricular dysfunction and arrhythmias, were reported in 41 percent of patients with merosin-deficient CMD [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H17"><span class="h2">Classic form</span><span class="headingEndMark"> — </span>The identification of pathogenic variants within the laminin alpha-2 chain gene (<em>LAMA2</em>; merosin) led to the subclassification of classic CMD into merosin-deficient and merosin-positive groups. The chromosomal loci and the respective genes that have been identified for these disorders are listed in the table (<a class="graphic graphic_table graphicRef67132" href="/d/graphic/67132.html" rel="external">table 2</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>Merosin-deficient CMD (MDC1A; MIM 607855) is characterized by a combination of severe CMD, demyelination of the cerebral hemispheres (typically without structural CNS anomalies) and high CK levels. Affected patients usually present with severe neonatal hypotonia, contractures, feeding difficulties, and muscle weakness affecting the upper limbs more severely than the lower limbs, which leads to delayed acquisition of motor milestones such as sitting and walking independently. Facial weakness is often pronounced and, in the second decade of life, extraocular muscle weakness may be noted as well (usually involving upgaze). Approximately, 20 to 30 percent of patients develop seizure disorders, usually later in childhood, and 5 to 10 percent of patients exhibit cognitive deficits [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1">The associated mutated gene (<em>LAMA2</em>) was mapped to chromosome 6q22-23 and identified as encoding the alpha-2 chain of laminin, also known as merosin [<a href="#rid42">42</a>]. The laminin alpha-2 chain is a component of the DAP complex (<a class="graphic graphic_figure graphicRef66588" href="/d/graphic/66588.html" rel="external">figure 1</a>). Disease-associated variants in the <em>LAMA2</em> gene can cause either the severe early-childhood phenotype or milder and atypical phenotypes now collectively known as the <em>LAMA2</em>-related muscular dystrophies [<a href="#rid43">43</a>]. Staining of muscle biopsies from these patients with antimerosin antibodies shows a partial or absent pattern of the protein [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Merosin-positive CMD without structural brain abnormalities usually has a milder phenotype. This group is clinically and genetically heterogeneous, and includes classic CMD without distinguishing features, rigid spine syndrome associated with pathogenic variants in the selenoprotein N1 (<em>SEPN1</em>) gene, CMD with hyperextensible distal joints (Ullrich type), and CMD with intellectual disability or sensory abnormalities (<a class="graphic graphic_table graphicRef67132" href="/d/graphic/67132.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef54811" href="/d/graphic/54811.html" rel="external">table 3</a>).</p><p></p><p class="headingAnchor" id="H18"><span class="h2">Ullrich congenital muscular dystrophy and Bethlem myopathy</span><span class="headingEndMark"> — </span>The presence of multiple proximal joint contractures and hyperextensible distal joints in a child with congenital generalized weakness is suggestive of Ullrich congenital muscular dystrophy (MIM 254090). The course is characterized by a progressive decline in motor and respiratory function in the first decade of life, with a majority confined to wheelchair by 11 years of age [<a href="#rid45">45</a>]. The phenotype was originally associated with recessive pathogenic variants in type VI collagen genes (<em>COL6A1</em>, <em>COL6A2</em>, and <em>COL6A3</em>), although dominant variants were subsequently reported [<a href="#rid46">46-53</a>].</p><p>Pathogenic variants in the same genes also cause Bethlem myopathy (MIM 158810), a relatively less severe disorder typically presenting with proximal weakness and flexion contractures involving primarily distal joints (eg, ankles and interphalangeal joints of the fingers) but also involving the knees, hips, elbows, shoulders, and neck [<a href="#rid54">54-56</a>]. Bethlem myopathy was originally associated with autosomal dominant pathogenic variants in <em>COL6A1</em>, <em>COL6A2</em>, and <em>COL6A3</em> genes; patients with compound heterozygous <em>COL6A2</em> pathogenic variants and recessive inheritance have been reported as well [<a href="#rid57">57,58</a>].</p><p>While Ullrich congenital muscular dystrophy and Bethlem myopathy were once believed to be separate entities, they are now considered to represent opposite ends of a phenotypic spectrum [<a href="#rid51">51</a>]. Genetic analysis of 49 patients with onset of symptoms during the first two years of life who had pathogenic variants in one of the COL6-encoding genes showed that homozygous stop-codon (nonsense) variants in the triple helix domains resulted in the most severe phenotypes in which ambulation was never achieved [<a href="#rid59">59</a>]. By contrast, dominant de novo in-frame exon skipping and glycine missense variants as well as compound heterozygous novel variants (nonsense/missense) were associated with a moderate-progressive or intermediate phenotypes [<a href="#rid60">60</a>].</p><p class="headingAnchor" id="H1689451"><span class="h2">Dystroglycanopathies</span><span class="headingEndMark"> — </span>The dystroglycanopathies are associated with pathogenic variants in different genes that cause defective post-translational modification of alpha-dystroglycan (<a class="graphic graphic_figure graphicRef66588" href="/d/graphic/66588.html" rel="external">figure 1</a>). They are both genetically and phenotypically heterogeneous. In current nomenclature, these phenotypes are referred to as the "MDDG" series and include a disease spectrum ranging from mild to severe forms of congenital muscular dystrophy to mild forms of limb-girdle muscular dystrophy. The dystroglycanopathies are characterized by a variety of developmental brain abnormalities, best identified on MRI, including lissencephaly, cerebellar cysts, pontine hypoplasia, and posterior concavity of the brainstem (bowing) [<a href="#rid61">61</a>].</p><p>Congenital muscular dystrophy-dystroglycanopathy with brain and eye anomalies (type A or MDDGA) includes the more severe phenotypes historically known as Walker-Warburg syndrome and Fukuyama congenital muscular dystrophy, and a milder phenotype called muscle-eye-brain disease (<a class="graphic graphic_table graphicRef67132" href="/d/graphic/67132.html" rel="external">table 2</a>). Congenital muscular dystrophy-dystroglycanopathy with or without intellectual disability (type B or MDDGB) is also genetically heterogeneous [<a href="#rid62">62-69</a>]. The type B phenotypes of congenital muscular dystrophy-dystroglycanopathy are less severe than the type A but more severe than the type C (limb-girdle muscular dystrophy-dystroglycanopathy) [<a href="#rid70">70</a>].</p><p>The phenotypes of congenital muscular dystrophy-dystroglycanopathy historically designated as Fukuyama, Walker-Warburg, and muscle-eye-brain disease (all now considered type A) are reviewed in the sections that follow.</p><p class="headingAnchor" id="H19"><span class="h3">Fukuyama type</span><span class="headingEndMark"> — </span>The Fukuyama type of CMD (MIM 253800) is among the most common autosomal recessive disorders in Japan (0.7 to 1.2 per 10,000 births) [<a href="#rid71">71</a>], and is characterized by hypotonia, generalized weakness, severe developmental delay, febrile seizures and/or epilepsy, microcephaly, and elevated serum CK levels (<a class="graphic graphic_table graphicRef54811" href="/d/graphic/54811.html" rel="external">table 3</a>) [<a href="#rid72">72</a>].</p><p>The electroencephalogram is abnormal in this disorder and shows epileptiform activity. Cortical dysgenesis is detected by cerebral computed tomography (CT) or MRI. The specific lesions are pachygyria and polymicrogyria in the temporal and occipital regions. Transient T2 hyperintensities appear in the white matter, and hypoplasia of the pons and cerebellar cysts may occur [<a href="#rid73">73</a>]. Ocular involvement is limited to simple myopia without structural changes. In a registry from Japan of patients with Fukuyama CMD, myopia was the most frequently diagnosed abnormality (9 percent), followed by strabismus (6 percent) [<a href="#rid74">74</a>]. Overall, 16 percent of patients needed respiratory support and this percentage increased with age. Cardiac dysfunction was diagnosed in 16 percent of patients, and dysphagia was noted in 22 percent.</p><p>The locus for the mutated Fukuyama-type (MDDGA4) congenital muscular dystrophy gene (<em>FKTN</em> gene) is located on chromosome 9q31-33 [<a href="#rid71">71,75</a>]. The respective protein, fukutin, is secreted outside the cell and may be a component of the extracellular matrix reinforcing muscle membranes [<a href="#rid73">73</a>]. Pathologic studies of the brain have suggested that fukutin is a constituent of the basement membrane [<a href="#rid76">76</a>].</p><p><em>FKTN</em> pathogenic variants have also been associated with severe dilated cardiomyopathy accompanied by a mild form of limb-girdle muscular dystrophy [<a href="#rid77">77</a>]. In addition, <em>FKTN</em> pathogenic variants have been identified in children with an LGMD phenotype and normal intelligence and brain structure designated muscular dystrophy-dystroglycanopathy (limb-girdle) type C4 (MDDGC4). (See  <a class="medical medical_review" href="/d/html/6190.html" rel="external">"Limb-girdle muscular dystrophy"</a>.)</p><p class="headingAnchor" id="H1689415"><span class="h3">Walker-Warburg syndrome</span><span class="headingEndMark"> — </span>Cerebro-ocular dysplasia or Walker-Warburg syndrome (WWS) is a type of CMD associated with ocular dysplasia, hydrocephalus, and cerebral malformations [<a href="#rid78">78-81</a>]. Ocular abnormalities include cataracts, optic nerve hypoplasia, corneal clouding, and retinal dysplasia or detachment. Serum CK concentration is mildly to moderately elevated in this disorder and the electrodiagnostic findings are myopathic. Brain MRI shows hypodense white matter, hypoplastic cerebellum and pons, ventricular dilatation (with or without hydrocephalus), and abnormal cortical development known as cobblestone type brain malformation (also called Type II lissencephaly). Other malformations include Dandy-Walker cyst, sometimes associated with posterior encephaloceles. The median survival is only four months.</p><p>The Walker-Warburg phenotype is associated with pathogenic variants in the <em>POMT1</em>, <em>POMT2</em>, <em>FKTN</em>, <em>FKRP</em>, <em>POMGNT1</em>, <em>LARGE</em>, <em>ISPD</em>, <em>GTDC2</em>, and <em>DAG1</em> genes [<a href="#rid63">63,64,82-93</a>]. These pathogenic variants cause defective glycosylation of alpha-dystroglycan complex (<a class="graphic graphic_figure graphicRef66588" href="/d/graphic/66588.html" rel="external">figure 1</a>) [<a href="#rid84">84</a>]. In current terminology (<a class="graphic graphic_table graphicRef67132" href="/d/graphic/67132.html" rel="external">table 2</a>), WWS associated with <em>POMT1</em> pathogenic variants (MIM 236670) is designated as muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies) type A1 (MDDGA1).</p><p>Other pathogenic variants in the <em>POMT1</em> gene are linked to a milder phenotype of congenital muscular dystrophy with microcephaly and intellectual disability, but without the ocular manifestations or structural brain malformations of WWS [<a href="#rid94">94</a>]. In addition, <em>POMT1</em> and <em>POMT2</em> gene pathogenic variants have been identified in children with subtypes of autosomal recessive limb-girdle muscular dystrophy (MDDGC1 and MDDGC2). (See  <a class="medical medical_review" href="/d/html/6190.html" rel="external">"Limb-girdle muscular dystrophy", section on 'Dystroglycanopathies'</a>.)</p><p class="headingAnchor" id="H21"><span class="h3">Muscle-eye-brain disease</span><span class="headingEndMark"> — </span>Muscle-eye-brain (MEB) disease has a milder phenotype than WWS [<a href="#rid95">95</a>]. The disorder is especially prevalent in Finland.</p><p>Patients with MEB typically present with hypotonia, severe progressive myopia from infancy, and developmental delay. Pale retina, low or flat electroretinogram, and visual failure related to retinal degeneration develop with advancing age. Seizures are common and cognitive impairment is often severe. At approximately five years of age, most patients decline motorically and develop contractures and spasticity [<a href="#rid96">96</a>].</p><p>Laboratory findings in MEB disease include an elevated serum CK level. Electromyography shows myopathic findings and the electroencephalogram is always abnormal. Brain MRI shows cobblestone lissencephaly, although it is less severe than in WWS; the brainstem in MEB disease is characteristically flat [<a href="#rid97">97</a>]. Ventriculomegaly and white matter hypodensities may also be seen [<a href="#rid98">98</a>]. Visual evoked potentials are delayed and giant (&gt;50 microvolts) in most patients [<a href="#rid95">95</a>].</p><p>Muscle biopsy usually shows dystrophic changes, although these may be minimal. Immunohistochemistry shows normal dystrophin and other dystrophin-associated proteins except for deficient alpha-dystroglycan [<a href="#rid99">99</a>].</p><p>The clinical phenotype of MEB can be caused by gene pathogenic variants of <em>POMGNT1</em> [<a href="#rid100">100-103</a>], <em>FKRP</em> [<a href="#rid87">87</a>], <em>POMT2</em> [<a href="#rid64">64,104</a>], <em>POMT1</em> [<a href="#rid62">62</a>], <em>FKTN</em> [<a href="#rid105">105</a>], and <em>LARGE</em> [<a href="#rid65">65</a>]. In current terminology (<a class="graphic graphic_table graphicRef67132" href="/d/graphic/67132.html" rel="external">table 2</a>), <em>POMGNT1</em>-related muscle-eye-brain disease (MIM 253280) is designated as muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies) type A3 (MDDGA3).</p><p class="headingAnchor" id="H22"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>For patients with a clinical presentation that is suspicious for CMD, we suggest an evaluation that includes cranial MRI, eye examination, and molecular genetic testing with next generation sequencing techniques [<a href="#rid106">106</a>]. A muscle biopsy for histology and immunostaining is indicated if the molecular genetic testing is negative, but muscle biopsy is not needed if a genetic diagnosis is made.</p><p>The infant with any type of CMD typically presents in the newborn period as a floppy baby, often with arthrogryposis. The clinical features are similar to those of an infant with a severe congenital myopathy, a disorder that is more frequent than the rare congenital muscular dystrophies. (See  <a class="medical medical_review" href="/d/html/6148.html" rel="external">"Approach to the infant with hypotonia and weakness"</a> and  <a class="medical medical_review" href="/d/html/6150.html" rel="external">"Congenital myopathies"</a>.)</p><p>MRI of the brain is useful to look for structural lesions or white matter abnormalities that accompany some CMDs. Examination of the eyes is important to exclude an ocular abnormality. The infant with a CMD has variably elevated serum CK levels.</p><p>Molecular genetic testing allows for confirmation of many forms of CMD, and testing is available for virtually all genes associated with CMD [<a href="#rid32">32,107</a>]; it has superseded muscle biopsy in most settings. However, no genetic diagnosis can be made in many cases, even with next generation sequencing techniques, suggesting that additional genetic causes of CMD remain to be identified [<a href="#rid106">106</a>].</p><p>The diagnosis can also be supported by muscle biopsy findings of wide-spread dystrophic changes or a myopathic pattern [<a href="#rid108">108</a>]. In infants lacking merosin, muscle immunohistochemical examination with antimerosin antibodies usually reveals complete or partial absence of this protein in the sarcolemma of the muscle fibers.</p><p>Patients with <em>LMNA</em>-related congenital muscular dystrophy may have prominent inflammatory changes on muscle biopsy and thus be misdiagnosed as having an inflammatory myopathy. In one series of 20 patients with early onset (age ≤2 years) inflammatory myopathy, heterozygous <em>LMNA</em> pathogenic variants were identified in 11 (55 percent) [<a href="#rid109">109</a>].</p><p class="headingAnchor" id="H23"><span class="h2">Management</span><span class="headingEndMark"> — </span>No definitive treatment is available for these disorders. However, multiorgan complications are common, and multidisciplinary care emphasizing surveillance and prompt interventions may be beneficial for affected children [<a href="#rid32">32</a>].</p><p>Monitoring recommendations for CMD, usually performed at least annually, consist of the following [<a href="#rid110">110</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac evaluation at diagnosis for all infants with CMD and periodic electrocardiography and echocardiography for those with or at risk for cardiac involvement</p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary function testing in sitting and supine positions</p><p class="bulletIndent1"><span class="glyph">●</span>Polysomnography for those with sleep disturbance or pulmonary function testing &lt;65 percent of predicted</p><p class="bulletIndent1"><span class="glyph">●</span>Nutrition parameters and growth measurements</p><p class="bulletIndent1"><span class="glyph">●</span>Assessment of swallowing and bulbar weakness</p><p class="bulletIndent1"><span class="glyph">●</span>Range of motion and orthopedic assessments</p><p></p><p>General management principles include the following [<a href="#rid38">38,39,110</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Measures to control weight and avoid obesity</p><p class="bulletIndent1"><span class="glyph">●</span>Physical therapy to improve mobility and avoid contractures</p><p class="bulletIndent1"><span class="glyph">●</span>Mechanical assistive devices to increase mobility and ambulation</p><p class="bulletIndent1"><span class="glyph">●</span>Surgery for orthopedic complications</p><p class="bulletIndent1"><span class="glyph">●</span>When beneficial, use of assisted cough, noninvasive ventilation, or tracheostomy and mechanical ventilation</p><p class="bulletIndent1"><span class="glyph">●</span>Social and emotional support</p><p></p><p class="headingAnchor" id="H2547478899"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/121073.html" rel="external">"Society guideline links: Muscular dystrophy"</a>.)</p><p class="headingAnchor" id="H24"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15489.html" rel="external">"Patient education: Muscular dystrophy (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/725.html" rel="external">"Patient education: Overview of muscular dystrophies (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H3508691849"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oculopharyngeal muscular dystrophy (OPMD)</strong> – This is a rare, slowly progressive myopathy that is characterized by ocular and pharyngeal muscle involvement, leading to ptosis, dysarthria, and dysphagia. Most cases of OPMD are caused by a GCN trinucleotide repeat expansion (where "N" represents any A, C, G, or T nucleotide) in the first exon of the <em>PABPN1 </em>gene. Treatment is supportive. (See <a class="local">'Oculopharyngeal muscular dystrophy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Distal muscular dystrophies</strong> – These disorders are a heterogeneous group of myopathies, as listed in the table (<a class="graphic graphic_table graphicRef51980" href="/d/graphic/51980.html" rel="external">table 1</a>). They are characterized by weakness that starts distally in the arms and/or legs and gradually progresses to affect proximal muscles. (See <a class="local">'Distal muscular dystrophies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Congenital muscular dystrophies (CMDs)</strong> – This category includes a number of genetically determined conditions in which muscular dystrophy is evident at birth or within the first two years of life. The original classification of the CMDs was based mainly upon the presence or absence of structural central nervous system abnormalities detected by neuroimaging or at autopsy (<a class="graphic graphic_table graphicRef54811" href="/d/graphic/54811.html" rel="external">table 3</a>). The absence of structural changes distinguished "occidental" or "classic" CMD from "syndromic" forms of CMD such as Fukuyama muscular dystrophy, Walker-Warburg syndrome, or muscle-eye-brain disease. However, the distinction is not entirely precise. The syndromic CMDs are caused by defective post-translational modification of alpha-dystroglycan (dystroglycanopathies) and other proteins, and they are caused by pathogenic variants in multiple genes (<a class="graphic graphic_table graphicRef67132" href="/d/graphic/67132.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1">For patients with a clinical presentation that is suspicious for CMD, we suggest an evaluation that includes cranial MRI, eye examination, and molecular genetic testing with next-generation sequencing techniques [<a href="#rid106">106</a>]. A muscle biopsy for histology and immunostaining is indicated if the molecular genetic testing is negative. No definitive treatment is available for these disorders. However, multiorgan complications are common, and multidisciplinary care emphasizing surveillance and prompt interventions may be beneficial for affected children, as described above. (See <a class="local">'Congenital muscular dystrophies'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">VICTOR M, HAYES R, ADAMS RD. Oculopharyngeal muscular dystrophy. A familial disease of late life characterized by dysphagia and progressive ptosis of the evelids. N Engl J Med 1962; 267:1267.</a></li><li class="breakAll">Trollet C, Gidaro T, Klein P, et al. Oculopharyngeal muscular dystrophy. GeneReviews. https://www.ncbi.nlm.nih.gov/books/NBK1126/ (Accessed on May 03, 2017).</li><li><a class="nounderline abstract_t">Alonso-Jimenez A, Kroon RHMJM, Alejaldre-Monforte A, et al. Muscle MRI in a large cohort of patients with oculopharyngeal muscular dystrophy. J Neurol Neurosurg Psychiatry 2019; 90:576.</a></li><li class="breakAll">Barbeau A. The symptom of hereditary late-onset ptosis and dysphagia in French-Canada. In: Symposium uber progressive muskeldystrophie, Kuhn E (Ed), Springer-Verlag, Berlin 1966. p.102.</li><li><a class="nounderline abstract_t">Blumen SC, Nisipeanu P, Sadeh M, et al. Epidemiology and inheritance of oculopharyngeal muscular dystrophy in Israel. Neuromuscul Disord 1997; 7 Suppl 1:S38.</a></li><li><a class="nounderline abstract_t">Blumen SC, Korczyn AD, Lavoie H, et al. Oculopharyngeal MD among Bukhara Jews is due to a founder (GCG)9 mutation in the PABP2 gene. Neurology 2000; 55:1267.</a></li><li><a class="nounderline abstract_t">Grewal RP, Karkera JD, Grewal RK, Detera-Wadleigh SD. Mutation analysis of oculopharyngeal muscular dystrophy in Hispanic American families. Arch Neurol 1999; 56:1378.</a></li><li><a class="nounderline abstract_t">Becher MW, Morrison L, Davis LE, et al. Oculopharyngeal muscular dystrophy in Hispanic New Mexicans. JAMA 2001; 286:2437.</a></li><li><a class="nounderline abstract_t">Brais B. Oculopharyngeal muscular dystrophy: a polyalanine myopathy. Curr Neurol Neurosci Rep 2009; 9:76.</a></li><li><a class="nounderline abstract_t">Raz V, Butler-Browne G, van Engelen B, Brais B. 191st ENMC international workshop: recent advances in oculopharyngeal muscular dystrophy research: from bench to bedside 8-10 June 2012, Naarden, The Netherlands. Neuromuscul Disord 2013; 23:516.</a></li><li><a class="nounderline abstract_t">Brais B, Bouchard JP, Xie YG, et al. Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. Nat Genet 1998; 18:164.</a></li><li><a class="nounderline abstract_t">Hebbar S, Webberley MJ, Lunt P, Robinson DO. Siblings with recessive oculopharyngeal muscular dystrophy. Neuromuscul Disord 2007; 17:254.</a></li><li><a class="nounderline abstract_t">Richard P, Trollet C, Gidaro T, et al. PABPN1 (GCN)11 as a Dominant Allele in Oculopharyngeal Muscular Dystrophy -Consequences in Clinical Diagnosis and Genetic Counselling. J Neuromuscul Dis 2015; 2:175.</a></li><li><a class="nounderline abstract_t">Calado A, Tomé FM, Brais B, et al. Nuclear inclusions in oculopharyngeal muscular dystrophy consist of poly(A) binding protein 2 aggregates which sequester poly(A) RNA. Hum Mol Genet 2000; 9:2321.</a></li><li><a class="nounderline abstract_t">Richard P, Trollet C, Stojkovic T, et al. Correlation between PABPN1 genotype and disease severity in oculopharyngeal muscular dystrophy. Neurology 2017; 88:359.</a></li><li><a class="nounderline abstract_t">Nishii YS, Noto YI, Yasuda R, et al. A Japanese case of oculopharyngeal muscular dystrophy (OPMD) with PABPN1 c.35G &gt; C; p.Gly12Ala point mutation. BMC Neurol 2021; 21:265.</a></li><li><a class="nounderline abstract_t">Blumen SC, Brais B, Korczyn AD, et al. Homozygotes for oculopharyngeal muscular dystrophy have a severe form of the disease. Ann Neurol 1999; 46:115.</a></li><li><a class="nounderline abstract_t">Blumen SC, Bouchard JP, Brais B, et al. Cognitive impairment and reduced life span of oculopharyngeal muscular dystrophy homozygotes. Neurology 2009; 73:596.</a></li><li><a class="nounderline abstract_t">Kim HJ, Mohassel P, Donkervoort S, et al. Heterozygous frameshift variants in HNRNPA2B1 cause early-onset oculopharyngeal muscular dystrophy. Nat Commun 2022; 13:2306.</a></li><li><a class="nounderline abstract_t">Duranceau A. Cricopharyngeal myotomy in the management of neurogenic and muscular dysphagia. Neuromuscul Disord 1997; 7 Suppl 1:S85.</a></li><li><a class="nounderline abstract_t">Youssof S, Schrader RM, Romero-Clark C, et al. Safety of botulinum toxin for dysphagia in oculopharyngeal muscular dystrophy. Muscle Nerve 2014; 49:601.</a></li><li><a class="nounderline abstract_t">Park RB, Akella SS, Aakalu VK. A review of surgical management of progressive myogenic ptosis. Orbit 2023; 42:11.</a></li><li><a class="nounderline abstract_t">Yamashita S. Recent Progress in Oculopharyngeal Muscular Dystrophy. J Clin Med 2021; 10.</a></li><li class="breakAll">Suominen T, Udd B, Hackman P. Udd distal myopathy. In: GeneReviews, Adam MP, Ardinger HH, Pagon RA, et al. (Eds), University of Washington, Seattle (WA) 1993-2013. https://www.ncbi.nlm.nih.gov/books/NBK1323/ (Accessed on July 31, 2019).</li><li><a class="nounderline abstract_t">Guergueltcheva V, Peeters K, Baets J, et al. Distal myopathy with upper limb predominance caused by filamin C haploinsufficiency. Neurology 2011; 77:2105.</a></li><li><a class="nounderline abstract_t">Schessl J, Kress W, Schoser B. Novel ANO5 mutations causing hyper-CK-emia, limb girdle muscular weakness and Miyoshi type of muscular dystrophy. Muscle Nerve 2012; 45:740.</a></li><li><a class="nounderline abstract_t">Bolduc V, Marlow G, Boycott KM, et al. Recessive mutations in the putative calcium-activated chloride channel Anoctamin 5 cause proximal LGMD2L and distal MMD3 muscular dystrophies. Am J Hum Genet 2010; 86:213.</a></li><li><a class="nounderline abstract_t">Hackman P, Sarparanta J, Lehtinen S, et al. Welander distal myopathy is caused by a mutation in the RNA-binding protein TIA1. Ann Neurol 2013; 73:500.</a></li><li><a class="nounderline abstract_t">Müller TJ, Kraya T, Stoltenburg-Didinger G, et al. Phenotype of matrin-3-related distal myopathy in 16 German patients. Ann Neurol 2014; 76:669.</a></li><li><a class="nounderline abstract_t">Johnson JO, Pioro EP, Boehringer A, et al. Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. Nat Neurosci 2014; 17:664.</a></li><li><a class="nounderline abstract_t">Bucelli RC, Arhzaouy K, Pestronk A, et al. SQSTM1 splice site mutation in distal myopathy with rimmed vacuoles. Neurology 2015; 85:665.</a></li><li><a class="nounderline abstract_t">Kang PB, Morrison L, Iannaccone ST, et al. Evidence-based guideline summary: evaluation, diagnosis, and management of congenital muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular &amp; Electrodiagnostic Medicine. Neurology 2015; 84:1369.</a></li><li><a class="nounderline abstract_t">Mercuri E, Muntoni F. The ever-expanding spectrum of congenital muscular dystrophies. Ann Neurol 2012; 72:9.</a></li><li><a class="nounderline abstract_t">Bönnemann CG, Wang CH, Quijano-Roy S, et al. Diagnostic approach to the congenital muscular dystrophies. Neuromuscul Disord 2014; 24:289.</a></li><li><a class="nounderline abstract_t">Schorling DC, Kirschner J, Bönnemann CG. Congenital Muscular Dystrophies and Myopathies: An Overview and Update. Neuropediatrics 2017; 48:247.</a></li><li><a class="nounderline abstract_t">Pini A, Merlini L, Tomé FM, et al. Merosin-negative congenital muscular dystrophy, occipital epilepsy with periodic spasms and focal cortical dysplasia. Report of three Italian cases in two families. Brain Dev 1996; 18:316.</a></li><li><a class="nounderline abstract_t">Messina S, Bruno C, Moroni I, et al. Congenital muscular dystrophies with cognitive impairment. A population study. Neurology 2010; 75:898.</a></li><li class="breakAll">Gordon E, Hoffman EP, Pegoraro E. Congenital muscular dystrophy overview. www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&amp;part=cmd-overview (Accessed on September 20, 2010).</li><li><a class="nounderline abstract_t">Finsterer J, Ramaciotti C, Wang CH, et al. Cardiac findings in congenital muscular dystrophies. Pediatrics 2010; 126:538.</a></li><li><a class="nounderline abstract_t">Bouman K, Gubbels M, van den Heuvel FMA, et al. Cardiac involvement in two rare neuromuscular diseases: LAMA2-related muscular dystrophy and SELENON-related myopathy. Neuromuscul Disord 2022; 32:635.</a></li><li><a class="nounderline abstract_t">Natera-de Benito D, Muchart J, Itzep D, et al. Epilepsy in LAMA2-related muscular dystrophy: An electro-clinico-radiological characterization. Epilepsia 2020; 61:971.</a></li><li><a class="nounderline abstract_t">Helbling-Leclerc A, Zhang X, Topaloglu H, et al. Mutations in the laminin alpha 2-chain gene (LAMA2) cause merosin-deficient congenital muscular dystrophy. Nat Genet 1995; 11:216.</a></li><li><a class="nounderline abstract_t">Oliveira J, Gruber A, Cardoso M, et al. LAMA2 gene mutation update: Toward a more comprehensive picture of the laminin-α2 variome and its related phenotypes. Hum Mutat 2018; 39:1314.</a></li><li><a class="nounderline abstract_t">Sarkozy A, Foley AR, Zambon AA, et al. LAMA2-Related Dystrophies: Clinical Phenotypes, Disease Biomarkers, and Clinical Trial Readiness. Front Mol Neurosci 2020; 13:123.</a></li><li><a class="nounderline abstract_t">Nadeau A, Kinali M, Main M, et al. Natural history of Ullrich congenital muscular dystrophy. Neurology 2009; 73:25.</a></li><li><a class="nounderline abstract_t">Camacho Vanegas O, Bertini E, Zhang RZ, et al. Ullrich scleroatonic muscular dystrophy is caused by recessive mutations in collagen type VI. Proc Natl Acad Sci U S A 2001; 98:7516.</a></li><li><a class="nounderline abstract_t">Demir E, Sabatelli P, Allamand V, et al. Mutations in COL6A3 cause severe and mild phenotypes of Ullrich congenital muscular dystrophy. Am J Hum Genet 2002; 70:1446.</a></li><li><a class="nounderline abstract_t">Pan TC, Zhang RZ, Sudano DG, et al. New molecular mechanism for Ullrich congenital muscular dystrophy: a heterozygous in-frame deletion in the COL6A1 gene causes a severe phenotype. Am J Hum Genet 2003; 73:355.</a></li><li><a class="nounderline abstract_t">Baker NL, Mörgelin M, Peat R, et al. Dominant collagen VI mutations are a common cause of Ullrich congenital muscular dystrophy. Hum Mol Genet 2005; 14:279.</a></li><li><a class="nounderline abstract_t">Giusti B, Lucarini L, Pietroni V, et al. Dominant and recessive COL6A1 mutations in Ullrich scleroatonic muscular dystrophy. Ann Neurol 2005; 58:400.</a></li><li><a class="nounderline abstract_t">Lampe AK, Bushby KM. Collagen VI related muscle disorders. J Med Genet 2005; 42:673.</a></li><li><a class="nounderline abstract_t">Fan Y, Liu A, Wei C, et al. Genetic and clinical findings in a Chinese cohort of patients with collagen VI-related myopathies. Clin Genet 2018; 93:1159.</a></li><li><a class="nounderline abstract_t">Mohassel P, Foley AR, Bönnemann CG. Extracellular matrix-driven congenital muscular dystrophies. Matrix Biol 2018; 71-72:188.</a></li><li><a class="nounderline abstract_t">Bethlem J, Wijngaarden GK. Benign myopathy, with autosomal dominant inheritance. A report on three pedigrees. Brain 1976; 99:91.</a></li><li><a class="nounderline abstract_t">Baker NL, Mörgelin M, Pace RA, et al. Molecular consequences of dominant Bethlem myopathy collagen VI mutations. Ann Neurol 2007; 62:390.</a></li><li><a class="nounderline abstract_t">Deconinck N, Richard P, Allamand V, et al. Bethlem myopathy: long-term follow-up identifies COL6 mutations predicting severe clinical evolution. J Neurol Neurosurg Psychiatry 2015; 86:1337.</a></li><li><a class="nounderline abstract_t">Gualandi F, Urciuolo A, Martoni E, et al. Autosomal recessive Bethlem myopathy. Neurology 2009; 73:1883.</a></li><li><a class="nounderline abstract_t">Caria F, Cescon M, Gualandi F, et al. Autosomal recessive Bethlem myopathy: A clinical, genetic and functional study. Neuromuscul Disord 2019; 29:657.</a></li><li><a class="nounderline abstract_t">Briñas L, Richard P, Quijano-Roy S, et al. Early onset collagen VI myopathies: Genetic and clinical correlations. Ann Neurol 2010; 68:511.</a></li><li><a class="nounderline abstract_t">Marakhonov AV, Tabakov VY, Zernov NV, et al. Two novel COL6A3 mutations disrupt extracellular matrix formation and lead to myopathy from Ullrich congenital muscular dystrophy and Bethlem myopathy spectrum. Gene 2018; 672:165.</a></li><li><a class="nounderline abstract_t">Brun BN, Mockler SR, Laubscher KM, et al. Comparison of brain MRI findings with language and motor function in the dystroglycanopathies. Neurology 2017; 88:623.</a></li><li><a class="nounderline abstract_t">Mercuri E, Messina S, Bruno C, et al. Congenital muscular dystrophies with defective glycosylation of dystroglycan: a population study. Neurology 2009; 72:1802.</a></li><li><a class="nounderline abstract_t">Yanagisawa A, Bouchet C, Van den Bergh PY, et al. New POMT2 mutations causing congenital muscular dystrophy: identification of a founder mutation. Neurology 2007; 69:1254.</a></li><li><a class="nounderline abstract_t">Godfrey C, Clement E, Mein R, et al. Refining genotype phenotype correlations in muscular dystrophies with defective glycosylation of dystroglycan. Brain 2007; 130:2725.</a></li><li><a class="nounderline abstract_t">Clement E, Mercuri E, Godfrey C, et al. Brain involvement in muscular dystrophies with defective dystroglycan glycosylation. Ann Neurol 2008; 64:573.</a></li><li><a class="nounderline abstract_t">Villanova M, Mercuri E, Bertini E, et al. Congenital muscular dystrophy associated with calf hypertrophy, microcephaly and severe mental retardation in three Italian families: evidence for a novel CMD syndrome. Neuromuscul Disord 2000; 10:541.</a></li><li><a class="nounderline abstract_t">Brockington M, Blake DJ, Prandini P, et al. Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin alpha2 deficiency and abnormal glycosylation of alpha-dystroglycan. Am J Hum Genet 2001; 69:1198.</a></li><li><a class="nounderline abstract_t">Mercuri E, Topaloglu H, Brockington M, et al. Spectrum of brain changes in patients with congenital muscular dystrophy and FKRP gene mutations. Arch Neurol 2006; 63:251.</a></li><li><a class="nounderline abstract_t">Longman C, Brockington M, Torelli S, et al. Mutations in the human LARGE gene cause MDC1D, a novel form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of alpha-dystroglycan. Hum Mol Genet 2003; 12:2853.</a></li><li><a class="nounderline abstract_t">D'haenens E, Vergult S, Menten B, et al. Expanding the Phenotype of B3GALNT2-Related Disorders. Genes (Basel) 2022; 13.</a></li><li><a class="nounderline abstract_t">Kobayashi K, Nakahori Y, Miyake M, et al. An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy. Nature 1998; 394:388.</a></li><li><a class="nounderline abstract_t">Kamoshita S, Konishi Y, Segawa M, Fukuyama Y. Congenital muscular dystrophy as a disease of the central nervous system. Arch Neurol 1976; 33:513.</a></li><li><a class="nounderline abstract_t">Toda T, Kobayashi K, Kondo-Iida E, et al. The Fukuyama congenital muscular dystrophy story. Neuromuscul Disord 2000; 10:153.</a></li><li><a class="nounderline abstract_t">Ishigaki K, Ihara C, Nakamura H, et al. National registry of patients with Fukuyama congenital muscular dystrophy in Japan. Neuromuscul Disord 2018; 28:885.</a></li><li><a class="nounderline abstract_t">Toda T, Segawa M, Nomura Y, et al. Localization of a gene for Fukuyama type congenital muscular dystrophy to chromosome 9q31-33. Nat Genet 1993; 5:283.</a></li><li><a class="nounderline abstract_t">Yamamoto T, Shibata N, Kanazawa M, et al. Early ultrastructural changes in the central nervous system in Fukuyama congenital muscular dystrophy. Ultrastruct Pathol 1997; 21:355.</a></li><li><a class="nounderline abstract_t">Murakami T, Hayashi YK, Noguchi S, et al. Fukutin gene mutations cause dilated cardiomyopathy with minimal muscle weakness. Ann Neurol 2006; 60:597.</a></li><li><a class="nounderline abstract_t">Suthar R, Angurana SK, Singh U, Singh P. Walker-Warburg syndrome. Neurol India 2018; 66:1849.</a></li><li><a class="nounderline abstract_t">Vajsar J, Schachter H. Walker-Warburg syndrome. Orphanet J Rare Dis 2006; 1:29.</a></li><li><a class="nounderline abstract_t">Agrawal S. Walker-Warburg syndrome. BMJ Case Rep 2011; 2011.</a></li><li><a class="nounderline abstract_t">Lee CY. Walker-Warburg syndrome: rare congenital muscular dystrophy associated with brain and eye abnormalities. Hong Kong Med J 2014; 20:556.e4.</a></li><li><a class="nounderline abstract_t">Beltrán-Valero de Bernabé D, Currier S, Steinbrecher A, et al. Mutations in the O-mannosyltransferase gene POMT1 give rise to the severe neuronal migration disorder Walker-Warburg syndrome. Am J Hum Genet 2002; 71:1033.</a></li><li><a class="nounderline abstract_t">van Reeuwijk J, Janssen M, van den Elzen C, et al. POMT2 mutations cause alpha-dystroglycan hypoglycosylation and Walker-Warburg syndrome. J Med Genet 2005; 42:907.</a></li><li><a class="nounderline abstract_t">van Reeuwijk J, Brunner HG, van Bokhoven H. Glyc-O-genetics of Walker-Warburg syndrome. Clin Genet 2005; 67:281.</a></li><li><a class="nounderline abstract_t">de Bernabé DB, van Bokhoven H, van Beusekom E, et al. A homozygous nonsense mutation in the fukutin gene causes a Walker-Warburg syndrome phenotype. J Med Genet 2003; 40:845.</a></li><li><a class="nounderline abstract_t">Silan F, Yoshioka M, Kobayashi K, et al. A new mutation of the fukutin gene in a non-Japanese patient. Ann Neurol 2003; 53:392.</a></li><li><a class="nounderline abstract_t">Beltran-Valero de Bernabé D, Voit T, Longman C, et al. Mutations in the FKRP gene can cause muscle-eye-brain disease and Walker-Warburg syndrome. J Med Genet 2004; 41:e61.</a></li><li><a class="nounderline abstract_t">Clement EM, Godfrey C, Tan J, et al. Mild POMGnT1 mutations underlie a novel limb-girdle muscular dystrophy variant. Arch Neurol 2008; 65:137.</a></li><li><a class="nounderline abstract_t">van Reeuwijk J, Grewal PK, Salih MA, et al. Intragenic deletion in the LARGE gene causes Walker-Warburg syndrome. Hum Genet 2007; 121:685.</a></li><li><a class="nounderline abstract_t">Willer T, Lee H, Lommel M, et al. ISPD loss-of-function mutations disrupt dystroglycan O-mannosylation and cause Walker-Warburg syndrome. Nat Genet 2012; 44:575.</a></li><li><a class="nounderline abstract_t">Roscioli T, Kamsteeg EJ, Buysse K, et al. Mutations in ISPD cause Walker-Warburg syndrome and defective glycosylation of α-dystroglycan. Nat Genet 2012; 44:581.</a></li><li><a class="nounderline abstract_t">Manzini MC, Tambunan DE, Hill RS, et al. Exome sequencing and functional validation in zebrafish identify GTDC2 mutations as a cause of Walker-Warburg syndrome. Am J Hum Genet 2012; 91:541.</a></li><li><a class="nounderline abstract_t">Riemersma M, Mandel H, van Beusekom E, et al. Absence of α- and β-dystroglycan is associated with Walker-Warburg syndrome. Neurology 2015; 84:2177.</a></li><li><a class="nounderline abstract_t">D'Amico A, Tessa A, Bruno C, et al. Expanding the clinical spectrum of POMT1 phenotype. Neurology 2006; 66:1564.</a></li><li><a class="nounderline abstract_t">Santavuori P, Somer H, Sainio K, et al. Muscle-eye-brain disease (MEB). Brain Dev 1989; 11:147.</a></li><li class="breakAll">Jones K, North K. The congenital muscular dystrophies. In: Neuromuscular Disorders of Infancy, Childhood, and Adolescence: A Clinician's Approach, Jones HR, De Vivo DC, Darras BT (Eds), Butterworth-Heinemann, Philadelphia 2003. p.633.</li><li><a class="nounderline abstract_t">Haltia M, Leivo I, Somer H, et al. Muscle-eye-brain disease: a neuropathological study. Ann Neurol 1997; 41:173.</a></li><li><a class="nounderline abstract_t">Valanne L, Pihko H, Katevuo K, et al. MRI of the brain in muscle-eye-brain (MEB) disease. Neuroradiology 1994; 36:473.</a></li><li><a class="nounderline abstract_t">Kano H, Kobayashi K, Herrmann R, et al. Deficiency of alpha-dystroglycan in muscle-eye-brain disease. Biochem Biophys Res Commun 2002; 291:1283.</a></li><li><a class="nounderline abstract_t">Yoshida A, Kobayashi K, Manya H, et al. Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. Dev Cell 2001; 1:717.</a></li><li><a class="nounderline abstract_t">Taniguchi K, Kobayashi K, Saito K, et al. Worldwide distribution and broader clinical spectrum of muscle-eye-brain disease. Hum Mol Genet 2003; 12:527.</a></li><li><a class="nounderline abstract_t">Vervoort VS, Holden KR, Ukadike KC, et al. POMGnT1 gene alterations in a family with neurological abnormalities. Ann Neurol 2004; 56:143.</a></li><li><a class="nounderline abstract_t">Cormand B, Avela K, Pihko H, et al. Assignment of the muscle-eye-brain disease gene to 1p32-p34 by linkage analysis and homozygosity mapping. Am J Hum Genet 1999; 64:126.</a></li><li><a class="nounderline abstract_t">Yanagisawa A, Bouchet C, Quijano-Roy S, et al. POMT2 intragenic deletions and splicing abnormalities causing congenital muscular dystrophy with mental retardation. Eur J Med Genet 2009; 52:201.</a></li><li><a class="nounderline abstract_t">Vuillaumier-Barrot S, Quijano-Roy S, Bouchet-Seraphin C, et al. Four Caucasian patients with mutations in the fukutin gene and variable clinical phenotype. Neuromuscul Disord 2009; 19:182.</a></li><li><a class="nounderline abstract_t">O'Grady GL, Lek M, Lamande SR, et al. Diagnosis and etiology of congenital muscular dystrophy: We are halfway there. Ann Neurol 2016; 80:101.</a></li><li><a class="nounderline abstract_t">Song D, Dai Y, Chen X, et al. Genetic variations and clinical spectrum of dystroglycanopathy in a large cohort of Chinese patients. Clin Genet 2021; 99:384.</a></li><li><a class="nounderline abstract_t">Peat RA, Smith JM, Compton AG, et al. Diagnosis and etiology of congenital muscular dystrophy. Neurology 2008; 71:312.</a></li><li><a class="nounderline abstract_t">Komaki H, Hayashi YK, Tsuburaya R, et al. Inflammatory changes in infantile-onset LMNA-associated myopathy. Neuromuscul Disord 2011; 21:563.</a></li><li><a class="nounderline abstract_t">Gilbreath HR, Castro D, Iannaccone ST. Congenital myopathies and muscular dystrophies. Neurol Clin 2014; 32:689.</a></li></ol></div><div id="topicVersionRevision">Topic 6180 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13997067" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Oculopharyngeal muscular dystrophy. A familial disease of late life characterized by dysphagia and progressive ptosis of the evelids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13997067" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Oculopharyngeal muscular dystrophy. A familial disease of late life characterized by dysphagia and progressive ptosis of the evelids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30530568" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Muscle MRI in a large cohort of patients with oculopharyngeal muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30530568" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Muscle MRI in a large cohort of patients with oculopharyngeal muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9392014" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Epidemiology and inheritance of oculopharyngeal muscular dystrophy in Israel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11087766" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Oculopharyngeal MD among Bukhara Jews is due to a founder (GCG)9 mutation in the PABP2 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10555658" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Mutation analysis of oculopharyngeal muscular dystrophy in Hispanic American families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11712939" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Oculopharyngeal muscular dystrophy in Hispanic New Mexicans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19080757" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Oculopharyngeal muscular dystrophy: a polyalanine myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23578714" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : 191st ENMC international workshop: recent advances in oculopharyngeal muscular dystrophy research: from bench to bedside 8-10 June 2012, Naarden, The Netherlands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9462747" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17296297" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Siblings with recessive oculopharyngeal muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27858728" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : PABPN1 (GCN)11 as a Dominant Allele in Oculopharyngeal Muscular Dystrophy -Consequences in Clinical Diagnosis and Genetic Counselling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11001936" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Nuclear inclusions in oculopharyngeal muscular dystrophy consist of poly(A) binding protein 2 aggregates which sequester poly(A) RNA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28011929" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Correlation between PABPN1 genotype and disease severity in oculopharyngeal muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34225694" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A Japanese case of oculopharyngeal muscular dystrophy (OPMD) with PABPN1 c.35G &gt; C; p.Gly12Ala point mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10401788" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Homozygotes for oculopharyngeal muscular dystrophy have a severe form of the disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19704078" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Cognitive impairment and reduced life span of oculopharyngeal muscular dystrophy homozygotes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35484142" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Heterozygous frameshift variants in HNRNPA2B1 cause early-onset oculopharyngeal muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9392023" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Cricopharyngeal myotomy in the management of neurogenic and muscular dysphagia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24259282" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Safety of botulinum toxin for dysphagia in oculopharyngeal muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36178005" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A review of surgical management of progressive myogenic ptosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33805441" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Recent Progress in Oculopharyngeal Muscular Dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33805441" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Recent Progress in Oculopharyngeal Muscular Dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22131542" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Distal myopathy with upper limb predominance caused by filamin C haploinsufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22499103" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Novel ANO5 mutations causing hyper-CK-emia, limb girdle muscular weakness and Miyoshi type of muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20096397" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Recessive mutations in the putative calcium-activated chloride channel Anoctamin 5 cause proximal LGMD2L and distal MMD3 muscular dystrophies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23401021" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Welander distal myopathy is caused by a mutation in the RNA-binding protein TIA1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25154462" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Phenotype of matrin-3-related distal myopathy in 16 German patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24686783" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26208961" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : SQSTM1 splice site mutation in distal myopathy with rimmed vacuoles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25825463" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Evidence-based guideline summary: evaluation, diagnosis, and management of congenital muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular&amp;Electrodiagnostic Medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22829265" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The ever-expanding spectrum of congenital muscular dystrophies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24581957" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Diagnostic approach to the congenital muscular dystrophies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28669131" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Congenital Muscular Dystrophies and Myopathies: An Overview and Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8879653" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Merosin-negative congenital muscular dystrophy, occipital epilepsy with periodic spasms and focal cortical dysplasia. Report of three Italian cases in two families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20820001" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Congenital muscular dystrophies with cognitive impairment. A population study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20820001" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Congenital muscular dystrophies with cognitive impairment. A population study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20679303" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Cardiac findings in congenital muscular dystrophies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35868898" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Cardiac involvement in two rare neuromuscular diseases: LAMA2-related muscular dystrophy and SELENON-related myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32266982" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Epilepsy in LAMA2-related muscular dystrophy: An electro-clinico-radiological characterization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7550355" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Mutations in the laminin alpha 2-chain gene (LAMA2) cause merosin-deficient congenital muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30055037" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : LAMA2 gene mutation update: Toward a more comprehensive picture of the laminin-α2 variome and its related phenotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32848593" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : LAMA2-Related Dystrophies: Clinical Phenotypes, Disease Biomarkers, and Clinical Trial Readiness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19564581" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Natural history of Ullrich congenital muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11381124" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Ullrich scleroatonic muscular dystrophy is caused by recessive mutations in collagen type VI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11992252" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Mutations in COL6A3 cause severe and mild phenotypes of Ullrich congenital muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12840783" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : New molecular mechanism for Ullrich congenital muscular dystrophy: a heterozygous in-frame deletion in the COL6A1 gene causes a severe phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15563506" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Dominant collagen VI mutations are a common cause of Ullrich congenital muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16130093" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Dominant and recessive COL6A1 mutations in Ullrich scleroatonic muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16141002" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Collagen VI related muscle disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29419890" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Genetic and clinical findings in a Chinese cohort of patients with collagen VI-related myopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29933045" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Extracellular matrix-driven congenital muscular dystrophies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/963533" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Benign myopathy, with autosomal dominant inheritance. A report on three pedigrees.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17886299" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Molecular consequences of dominant Bethlem myopathy collagen VI mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25535305" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Bethlem myopathy: long-term follow-up identifies COL6 mutations predicting severe clinical evolution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19949035" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Autosomal recessive Bethlem myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31471117" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Autosomal recessive Bethlem myopathy: A clinical, genetic and functional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20976770" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Early onset collagen VI myopathies: Genetic and clinical correlations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29894794" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Two novel COL6A3 mutations disrupt extracellular matrix formation and lead to myopathy from Ullrich congenital muscular dystrophy and Bethlem myopathy spectrum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28087826" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Comparison of brain MRI findings with language and motor function in the dystroglycanopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19299310" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Congenital muscular dystrophies with defective glycosylation of dystroglycan: a population study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17634419" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : New POMT2 mutations causing congenital muscular dystrophy: identification of a founder mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17878207" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Refining genotype phenotype correlations in muscular dystrophies with defective glycosylation of dystroglycan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19067344" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Brain involvement in muscular dystrophies with defective dystroglycan glycosylation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11053679" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Congenital muscular dystrophy associated with calf hypertrophy, microcephaly and severe mental retardation in three Italian families: evidence for a novel CMD syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11592034" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin alpha2 deficiency and abnormal glycosylation of alpha-dystroglycan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16476814" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Spectrum of brain changes in patients with congenital muscular dystrophy and FKRP gene mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12966029" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Mutations in the human LARGE gene cause MDC1D, a novel form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of alpha-dystroglycan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35456500" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Expanding the Phenotype of B3GALNT2-Related Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9690476" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/938276" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Congenital muscular dystrophy as a disease of the central nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10734260" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The Fukuyama congenital muscular dystrophy story.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30220444" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : National registry of patients with Fukuyama congenital muscular dystrophy in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8275093" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Localization of a gene for Fukuyama type congenital muscular dystrophy to chromosome 9q31-33.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9206000" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Early ultrastructural changes in the central nervous system in Fukuyama congenital muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17036286" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Fukutin gene mutations cause dilated cardiomyopathy with minimal muscle weakness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30504606" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Walker-Warburg syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16887026" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Walker-Warburg syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22691590" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Walker-Warburg syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25488038" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Walker-Warburg syndrome: rare congenital muscular dystrophy associated with brain and eye abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12369018" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Mutations in the O-mannosyltransferase gene POMT1 give rise to the severe neuronal migration disorder Walker-Warburg syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15894594" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : POMT2 mutations cause alpha-dystroglycan hypoglycosylation and Walker-Warburg syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15733261" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Glyc-O-genetics of Walker-Warburg syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14627679" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : A homozygous nonsense mutation in the fukutin gene causes a Walker-Warburg syndrome phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12601708" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : A new mutation of the fukutin gene in a non-Japanese patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15121789" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Mutations in the FKRP gene can cause muscle-eye-brain disease and Walker-Warburg syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18195152" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Mild POMGnT1 mutations underlie a novel limb-girdle muscular dystrophy variant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17436019" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Intragenic deletion in the LARGE gene causes Walker-Warburg syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22522420" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : ISPD loss-of-function mutations disrupt dystroglycan O-mannosylation and cause Walker-Warburg syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22522421" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Mutations in ISPD cause Walker-Warburg syndrome and defective glycosylation ofα-dystroglycan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22958903" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Exome sequencing and functional validation in zebrafish identify GTDC2 mutations as a cause of Walker-Warburg syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25934851" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Absence ofα- andβ-dystroglycan is associated with Walker-Warburg syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16717220" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Expanding the clinical spectrum of POMT1 phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2751061" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Muscle-eye-brain disease (MEB)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2751061" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Muscle-eye-brain disease (MEB)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9029066" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Muscle-eye-brain disease: a neuropathological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7991095" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : MRI of the brain in muscle-eye-brain (MEB) disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11883957" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Deficiency of alpha-dystroglycan in muscle-eye-brain disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11709191" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12588800" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Worldwide distribution and broader clinical spectrum of muscle-eye-brain disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15236414" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : POMGnT1 gene alterations in a family with neurological abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9915951" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Assignment of the muscle-eye-brain disease gene to 1p32-p34 by linkage analysis and homozygosity mapping.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19138766" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : POMT2 intragenic deletions and splicing abnormalities causing congenital muscular dystrophy with mental retardation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19179078" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Four Caucasian patients with mutations in the fukutin gene and variable clinical phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27159402" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Diagnosis and etiology of congenital muscular dystrophy: We are halfway there.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33200426" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Genetic variations and clinical spectrum of dystroglycanopathy in a large cohort of Chinese patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18160674" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Diagnosis and etiology of congenital muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21632249" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Inflammatory changes in infantile-onset LMNA-associated myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25037085" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Congenital myopathies and muscular dystrophies.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
